State-of-the-Art-Review : Statins Induce Hypothrombotic States?
- 1 January 2000
- journal article
- review article
- Published by SAGE Publications in Clinical and Applied Thrombosis/hemostasis
- Vol. 6 (1) , 18-21
- https://doi.org/10.1177/107602960000600103
Abstract
Statins inhibit 3-hydroxy-3-methyl-glutaryl coenzyme A (HMGCoA) reductase, which synthesizes mevalonic acid in the isoprenoid pathways. These pathways lead to squalene and subsequently to cholesterol and related products (e.g., steroids, vitamin D, bile salts, lipopro teins) and have major branches producing cell regulatory substances (e.g., farnesyl- and geranylgeranyl conjugated proteins) (1,2). Although cholesterol reduc tion in blood has been widely believed to be beneficial (e.g., less available for accumulation by foam cells in atherosclerotic plaques), the ability of cholesterol reduc tion to mitigate the incidence and severity of cardiovas cular diseases has recently been questioned. Like others (3-10), we (11) believe that statins and other substances, for example, plant isoprenoids in the diet (12), have ben eficial antithrombotic properties arising through the in hibition of an isoprenoid product other than cholesterol. However, unlike others, we also believe that this isopren oid product has cell regulatory functions upregulated by thrombin stimulation. Moreover, through such cellular pathways, thrombin should upregulate its own genera tion, and statins and dietary isoprenoids should induce hypothrombotic states by downregulating thrombin gen eration (Fig. 1).Keywords
This publication has 34 references indexed in Scilit:
- Statins as Cellular AntithromboticsPathophysiology of Haemostasis and Thrombosis, 1999
- Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemiaJournal of the American College of Cardiology, 1999
- Antiatherothrombotic Properties of StatinsJAMA, 1998
- Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemiaThe Lancet, 1997
- Vastatins Inhibit Tissue Factor in Cultured Human MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Statins do more than just lower cholesterolThe Lancet, 1996
- Can the clinical efficacy of the HMG CoA reductase inhibitors be explained solely by their effects on LDL-cholesterol?Atherosclerosis, 1996
- Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?The Lancet, 1996
- Posttranslational modification of proteins by isoprenoids in mammalian cellsThe FASEB Journal, 1990
- Regulation of the mevalonate pathwayNature, 1990